FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial

Epidermal growth factor receptor (EGFR) and hepatocyte growth factor (HGF)/mesenchymal –epithelial transition (MET) pathways, which promote tumour growth and proliferation, are often deregulated in advanced gastroesophageal adenocarcinomas. We assessed whether adding panitumumab (an EGFR inhibitor) or rilotumumab (a HGF inhibitor) to first-line fluoropyrimidine-based and platinum-ba sed chemotherapy (modified oxaliplatin, leucovorin and fluorouracil [mFOLFOX6]) benefits to patients with advanced gastroesophageal adenocarcinoma.

Source: European Journal of Cancer - May 22, 2019 Category: Cancer & Oncology Authors: David Malka, Eric Fran çois, Frédérique Penault-Llorca, Florence Castan, Olivier Bouché, Jaafar Bennouna, François Ghiringhelli, Christelle de la Fouchardière, Christophe Borg, Emmanuelle Samalin, Jean-Baptiste Bachet, Jean-Luc Raoul, Laurent Miglia Tags: Clinical Trial Source Type: research